首页> 美国卫生研究院文献>Purinergic Signalling >Synthesis biological activity and molecular modelling studies of tricyclic alkylimidazo- pyrimido- and diazepinopurinediones
【2h】

Synthesis biological activity and molecular modelling studies of tricyclic alkylimidazo- pyrimido- and diazepinopurinediones

机译:三环烷基咪唑基嘧啶基和二氮杂pin啶二酮的合成生物活性和分子模型研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Syntheses and biological activities of imidazo-, pyrimido- and diazepino[2,1-f]purinediones containing N-alkyl substituents (with straight, branched or unsaturated chains) are described. Tricyclic derivatives were synthesized by the cyclization of 8-bromo-substituted 7-(2-bromoethyl)-, 7-(3-chloropropyl)- or 7-(4-bromobutyl)-theophylline with primary amines under various conditions. Compound >22 with an ethenyl substituent was synthesized by dehydrohalogenation of 9-(2-bromoethyl)-1,3-dimethyltetrahydropyrimido[2,1-f]purinedione. The obtained derivatives (>5–>35) were initially evaluated for their affinity at rat A1 and A2A adenosine receptors (AR), showing moderate affinity for both adenosine receptor subtypes. The best ligands were diazepinopurinedione >28 (Ki = 0.28 μM) with fivefold A2A selectivity and the non-selective A1/A2A AR ligand pyrimidopurinedione >35 (Ki A1 = 0.28 μM and Ki A2A = 0.30 μM). The compounds were also evaluated for their affinity at human A1, A2A, A2B and A3 ARs. All of the obtained compounds were docked to the A2A AR X-ray structure in complex with the xanthine-based, potent adenosine receptor antagonist—XAC. The likely interactions of imidazo-, pyrimido- and diazepino[2,1-f]purinediones with the residues forming the A2A binding pocket were discussed. Furthermore, the new compounds were tested in vivo as anticonvulsants in maximal electroshock, subcutaneous pentylenetetrazole (ScMet) and TOX tests in mice (i.p.). Pyrimidopurinediones showed anticonvulsant activity mainly in the ScMet test. The best derivative was compound >11, showing 100 % protection at a dose of 100 mg/kg without symptoms of neurotoxicity. Compounds >6, >7, >8 and >14 with short substituents showed neurotoxicity and caused death. In rat tests (p.o.), >9 was characterized by a high protection index (>13.3). AR affinity did not apparently correlate with the antiepileptic potency of the compounds.Electronic supplementary materialThe online version of this article (doi:10.1007/s11302-013-9358-3) contains supplementary material, which is available to authorized users.
机译:描述了含有N-烷基取代基(具有直链,支链或不饱和链)的咪唑基,嘧啶基和二氮杂环庚烷[2,1-f]嘌呤二酮的合成和生物活性。通过在各种条件下用伯胺环化8-溴取代的7-(2-溴乙基)-,7-(3-氯丙基)-或7-(4-溴丁基)-茶碱来合成三环衍生物。通过9-(2-溴乙基)-1,3-二甲基四氢嘧啶[2,1-f]嘌呤二酮的脱卤化氢合成具有乙烯基取代基的化合物> 22 。首先评估获得的衍生物(> 5 – > 35 )对大鼠A1和A2A腺苷受体(AR)的亲和力,显示出对两种腺苷受体亚型的中等亲和力。最好的配体是重氮杂嘌呤二酮> 28 (Ki =0.28μM),具有2倍的A2A选择性和非选择性的A1 / A2A AR配体嘧啶嘌呤二酮> 35 (Ki A1 =0.28μM和Ki A2A =0.30μM)。还评估了化合物对人A1,A2A,A2B和A3 AR的亲和力。将所有获得的化合物与基于黄嘌呤的有效腺苷受体拮抗剂XAC结合到A2A AR X射线结构中。讨论了咪唑基,嘧啶基和二氮杂az [2,1-f]嘌呤二酮与形成A2A结合袋的残基的可能相互作用。此外,新化合物作为抗惊厥药在体内进行了最大电击,皮下戊烯四唑(ScMet)和TOX小鼠试验(i.p.)测试。嘧啶嘌呤二酮主要在ScMet试验中显示出抗惊厥活性。最好的衍生物是化合物> 11 ,在100 mg / kg的剂量下显示100%的保护作用,而没有神经毒性的症状。具有短取代基的化合物> 6 ,> 7 ,> 8 和> 14 显示神经毒性并引起死亡。在大鼠测试中(p.o。),> 9 具有较高的保护指数(> 13.3)。 AR亲和力与这些化合物的抗癫痫药效力没有明显关系。电子补充材料本文的在线版本(doi:10.1007 / s11302-013-9358-3)包含补充材料,授权用户可以使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号